Recce is an emerging leader in the new generation of synthetic antibiotic therapies.
We are developing a diverse portfolio of synthetic antibiotics designed to address the real and growing threat to human health from antibiotic resistant bacteria.
Our current pre-clinical programs target under-served therapeutic areas with large unmet global needs.
These include sepsis (blood poisoning), H.pylori (stomach ulcers) and E. coli (diarrhoea).
We are also developing complimentary capabilities of our lead product candidate to augment its capability as a bacterial antibiotic.
Our Vision & Values
“To target the global health problem of superbugs”
New synthetic (polymer based) drugs are uniquely used for targeting major human health threats. With over 30 years of polymer experience, Dr Melrose and team are well placed to broaden Recce’s technical capabilities.
Patents are the value of any technology company and Recce is no exception. With a track record of applying for a patent and it always being accepted, Recce is well positioned to continue expanding its international patent portfolio.
As an Australian Stock Exchange (ASX:RCE) listed company, Recce is funded to pursue its drug development activities with the U.S. Food and Drug Administration. Recce’s capitalistic culture sees all technical endeavours focused around a commercial outcome.